Immune Globulin Intravenous Articles
Octapharma submits BLA to US FDA for octagam 10%
24 September 2009
Talecris Gamunex beats placebo in CIDP trial
27 April 2009
Baxter presents data validating Gammagard
23 March 2009
Halozyme gets $5.5M Baxter payment
12 January 2009
Biovitrum/Symphogen completes proof-of-principle study
24 November 2008
Talecris buy could see CSL become leader in IVIG sales, says AMR
24 November 2008
Baxter sales up 15% in 3rd-qtr 2008
27 October 2008
Baxter initiates Ph III AD trial for Gammagard
29 September 2008
FDA approves Talecris' orphan drug for CIDP
22 September 2008
Possible role for Gammagard in AD
28 April 2008
CSL Behring enters deal for Canada
14 April 2008
Cangene gets orphan status for HepaGam
7 April 2008
CHMP grants positive opinion to CSL's Privigen
3 March 2008
Talecris' Gamunex cuts disability in CIDP
18 February 2008
FDA clears CSL Behring's Rhophylac for ITP
9 April 2007
FDA clears CSL Behring's Rhophylac for ITP
9 April 2007
Australia's CSL to up R&D expenditure
2 April 2007
Baxter's 4th-qtr net earnings up 47%
5 February 2007
ZLB buys MedImmune's CytoGam for $50M
22 December 2006
MedImmune sells CytoGam to ZLB Behring
13 November 2006
Bayer divests plasma business for $590M
20 December 2004
MedImmune's 2nd-qtr plunges into loss
2 August 2004
FDA OKs Octapharma's IGIV product
31 May 2004
Spain's Probitas gets FDA approval for its IVIG Flebogamma
19 January 2004
Bayer Biological gains Gamunex trade mark
30 June 2003
Baxter starts Ph III trial of new immune globulin
22 July 2002
HMO "not dropping Prozac or Prilosec"
21 April 1999
FDA Clears MedImmune's Synagis For RSV
22 June 1998
MedImmune Granted Canadian Approval For RespiGam
28 August 1997
Second Application For RespiGam
8 July 1996
Neozyme II And Nabi To Cease HyperGam+ Trial
1 July 1996
RespiGam Licensed In First Market
29 January 1996
PREVENT Trial Results Presented
24 July 1995
Univax Biologics Focusing On Core Activities
22 May 1995
US FDA Approves Univax' WinRho
3 April 1995
Showing 1-40 of 40 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
